Comparative dose study of a theophylline sustained-release tablet formulation after repeated administrations. 1989

D Cova, and G Cuglituri, and L Rossini, and G Bonfardeci
IV Medical Department, S. Carlo Borromeo General Hospital, Milano, Italy.

Two different doses of a sustained-release tablet formulation of theophylline were administered to two groups of patients affected by chronic obstructive pulmonary disease. Pharmacokinetic parameters were determined after a single administration of the drug. In this experiment, the theophylline plasma levels were determined 1, 2, 4, 8, 12 and 24 h after the drug administration. In another experiment, the patients received the drug "once-daily", in the morning, for nine consecutive days. Plasma theophylline levels were monitored 24 h after the first administration and twice daily on days 3, 6 and 9. Patients receiving 700 mg/day showed theophylline levels ranging from 8.49 +/- 1.04 micrograms/ml to 20.99 +/- 2.09 micrograms/ml. In this group theophylline concentrations were found to be greater than 10 micrograms/ml also 24 h after the tablets' administration. These data show that in case of single daily theophylline administration an high dosage is necessary to maintain the drug concentration within the range of therapeutic levels.

UI MeSH Term Description Entries
D008173 Lung Diseases, Obstructive Any disorder marked by obstruction of conducting airways of the lung. AIRWAY OBSTRUCTION may be acute, chronic, intermittent, or persistent. Obstructive Lung Diseases,Obstructive Pulmonary Diseases,Lung Disease, Obstructive,Obstructive Lung Disease,Obstructive Pulmonary Disease,Pulmonary Disease, Obstructive,Pulmonary Diseases, Obstructive
D008297 Male Males
D003692 Delayed-Action Preparations Dosage forms of a drug that act over a period of time by controlled-release processes or technology. Controlled Release Formulation,Controlled-Release Formulation,Controlled-Release Preparation,Delayed-Action Preparation,Depot Preparation,Depot Preparations,Extended Release Formulation,Extended Release Preparation,Prolonged-Action Preparation,Prolonged-Action Preparations,Sustained Release Formulation,Sustained-Release Preparation,Sustained-Release Preparations,Timed-Release Preparation,Timed-Release Preparations,Controlled-Release Formulations,Controlled-Release Preparations,Extended Release Formulations,Extended Release Preparations,Slow Release Formulation,Sustained Release Formulations,Controlled Release Formulations,Controlled Release Preparation,Controlled Release Preparations,Delayed Action Preparation,Delayed Action Preparations,Formulation, Controlled Release,Formulations, Controlled Release,Prolonged Action Preparation,Release Formulation, Controlled,Release Formulations, Controlled,Sustained Release Preparation,Timed Release Preparation,Timed Release Preparations
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D013806 Theophylline A methyl xanthine derivative from tea with diuretic, smooth muscle relaxant, bronchial dilation, cardiac and central nervous system stimulant activities. Theophylline inhibits the 3',5'-CYCLIC NUCLEOTIDE PHOSPHODIESTERASE that degrades CYCLIC AMP thus potentiates the actions of agents that act through ADENYLYL CYCLASES and cyclic AMP. 1,3-Dimethylxanthine,3,7-Dihydro-1,3-dimethyl-1H-purine-2,6-dione,Accurbron,Aerobin,Aerolate,Afonilum Retard,Aquaphyllin,Armophylline,Bronchoparat,Bronkodyl,Constant-T,Elixophyllin,Euphylong,Glycine Theophyllinate,Lodrane,Monospan,Nuelin,Nuelin S.A.,Quibron T-SR,Slo-Phyllin,Somophyllin-T,Sustaire,Synophylate,Theo Von Ct,Theo-24,Theo-Dur,Theobid,Theocin,Theoconfin Continuous,Theodur,Theolair,Theolix,Theon,Theonite,Theopek,Theophylline Anhydrous,Theophylline Sodium Glycinate,Theospan,Theostat,Theovent,Uniphyl,Uniphyllin,Uniphylline,1,3 Dimethylxanthine,Anhydrous, Theophylline,Constant T,ConstantT,Ct, Theo Von,Glycinate, Theophylline Sodium,Quibron T SR,Quibron TSR,Slo Phyllin,SloPhyllin,Sodium Glycinate, Theophylline,Somophyllin T,SomophyllinT,Theo 24,Theo Dur,Theo24,Theophyllinate, Glycine,Von Ct, Theo

Related Publications

D Cova, and G Cuglituri, and L Rossini, and G Bonfardeci
October 1987, International journal of clinical pharmacology, therapy, and toxicology,
D Cova, and G Cuglituri, and L Rossini, and G Bonfardeci
November 1987, Arerugi = [Allergy],
D Cova, and G Cuglituri, and L Rossini, and G Bonfardeci
January 1984, British journal of clinical practice. Supplement,
D Cova, and G Cuglituri, and L Rossini, and G Bonfardeci
December 1980, Annals of allergy,
D Cova, and G Cuglituri, and L Rossini, and G Bonfardeci
October 1986, International journal of clinical pharmacology, therapy, and toxicology,
D Cova, and G Cuglituri, and L Rossini, and G Bonfardeci
April 1980, British journal of clinical pharmacology,
D Cova, and G Cuglituri, and L Rossini, and G Bonfardeci
March 1986, Yao xue xue bao = Acta pharmaceutica Sinica,
D Cova, and G Cuglituri, and L Rossini, and G Bonfardeci
November 1983, American heart journal,
D Cova, and G Cuglituri, and L Rossini, and G Bonfardeci
December 1973, European journal of clinical pharmacology,
D Cova, and G Cuglituri, and L Rossini, and G Bonfardeci
October 1974, Clinical pharmacology and therapeutics,
Copied contents to your clipboard!